EUVIMEDEUVIMED entdecken
Crossref

SU5, a Stable Auraptene Analog, Ameliorates Metabolic Dysfunction‐Associated Steatohepatitis Through Modulation of the FXR Signaling Pathway

Fen Wen, Jing Chen, Lei Zhu, Siyu Xia, Yang Huang iD, Dezhi Bian iD

Drug Development Research · 2026-11 · 87 (7)

DOI: 10.1002/ddr.70404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 29.10.2026. Verfasst von Fen Wen und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, Yancheng, Jiangsu, China. Hauptthemen laut MEDLINE: Coumarins, Receptors, Cytoplasmic and Nuclear, Fatty Liver. Die Arbeit nennt 30 Literaturangaben. Gefördert von: Scientific Research Project of Yancheng Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic Dysfunction‐Associated Steatohepatitis (MASH), a metabolic liver disease severely threatening public health, is characterized by hepatic steatosis, inflammatory infiltration, and fibrotic progression. Currently, there is still a lack of specific therapeutic approaches for MASH in clinical practice. Auraptene (AUR), a natural citrus‐derived compound with demonstrated therapeutic potential against MASH, is limited in clinical translation by poor metabolic stability. To address this challenge, we evaluated the effects and mechanisms of SU5, a novel auraptene analog engineered for enhanced metabolic stability, in a MASH mouse model induced by a high‐fat/high‐sugar diet combined with carbon tetrachloride (CCl 4 ). SU5 treatment effectively reduced hepatic steatosis, inflammation, and fibrosis in MASH mice. It activated the FXR pathway, regulating bile acid metabolism‐related genes. SU5 also suppressed lipogenic genes, decreased inflammatory factors, and restored lipid homeostasis. Outperforming auraptene, SU5 is a promising MASH treatment option due to its enhanced stability.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CoumarinsReceptors, Cytoplasmic and NuclearFatty LiverAnimalsSignal TransductionReceptor, Farnesoid X-ActivatedMiceMaleMice, Inbred C57BLDiet, High-FatCarbon TetrachlorideHumansDisease Models, Animal

Stichwörter der Autor:innen

Farnesoid X receptor (FXR) signaling pathwaySU5aurapteneinflammationmetabolic dysfunction‐associated steatohepatitis (MASH)

Substanzen

CoumarinsauraptenReceptors, Cytoplasmic and NuclearReceptor, Farnesoid X-ActivatedCarbon Tetrachloride

Autor:innen und Institutionen

  • The Yancheng Clinical College of Xuzhou Medical University, The First People's Hospital of Yancheng, Yancheng, Jiangsu, China.
  • Xuzhou Medical University, Xuzhou, Jiangsu, China.

ORCID-Profile: Yang Huang, Dezhi Bian

Förderung

  • Scientific Research Project of Yancheng Health Commission

Zitieren

APA

Wen, F., Chen, J., Zhu, L., Xia, S., Huang, Y., & Bian, D. (2026). SU5, a Stable Auraptene Analog, Ameliorates Metabolic Dysfunction‐Associated Steatohepatitis Through Modulation of the FXR Signaling Pathway. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70404

Vancouver

Wen F, Chen J, Zhu L, Xia S, Huang Y, Bian D. SU5, a Stable Auraptene Analog, Ameliorates Metabolic Dysfunction‐Associated Steatohepatitis Through Modulation of the FXR Signaling Pathway. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70404

BibTeX
@article{Wen2026,
  author = {Wen, Fen and Chen, Jing and Zhu, Lei and Xia, Siyu and Huang, Yang and Bian, Dezhi},
  title = {SU5, a Stable Auraptene Analog, Ameliorates Metabolic Dysfunction‐Associated Steatohepatitis Through Modulation of the FXR Signaling Pathway},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {7},
  doi = {10.1002/ddr.70404}
}
Kostenlos starten →